Simple image-based no-wash method for quantitative detection of surface expressed CFTR

Methods

Volumn 96, Issue , 2016, Pages 40-45

  Larsen, Mads Breum ^a   Hu, Jennifer ^a   Frizzell, Raymond A ^b   Watkins, Simon C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Corrector; F508del CFTR; Fluorogen activating protein tag; High throughput screening; Surface expression

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; LUMACAFTOR; MEMBRANE PROTEIN; MUTANT PROTEIN; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPYRIDINE DERIVATIVE; CFTR PROTEIN, HUMAN; FLUORESCENT DYE; FUCHSINE; HYBRID PROTEIN; MALACHITE GREEN; MOLECULAR LIBRARY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANION TRANSPORT; ARTICLE; CELL SURFACE; DRUG DEVELOPMENT; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; AGONISTS; CELL MEMBRANE; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; METABOLISM; MOLECULAR IMAGING; MOLECULAR LIBRARY; MUTATION; PHARMACOLOGY; PLASMID; PROTEIN ENGINEERING;

AMINOPYRIDINES; BENZODIOXOLES; CELL MEMBRANE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FLUORESCENT DYES; GENE EXPRESSION; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MOLECULAR IMAGING; MUTATION; PLASMIDS; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; ROSANILINE DYES; SINGLE-CHAIN ANTIBODIES; SMALL MOLECULE LIBRARIES; TRANSFECTION;

EID: 84958168944     PISSN: 10462023     EISSN: 10959130     Source Type: Journal    
DOI: 10.1016/j.ymeth.2015.09.006     Document Type: Article

References (16)

1. Van Goor F., Hadida S., Grootenhuis P.D.J., Burton B., Stack J.H., Straley K.S., et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci. USA 2011, 108:18843-18848. 10.1073/pnas.1105787108.
2. Clancy J.P., Rowe S.M., Accurso F.J., Aitken M.L., Amin R.S., Ashlock M.A., et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012, 67:12-18. 10.1136/thoraxjnl-2011-200393.
3. Pedemonte N., Tomati V., Sondo E., Galietta L.J.V. Influence of cell background on pharmacological rescue of mutant CFTR. Am. J. Physiol. Cell Physiol. 2010, 298:C866-C874. 10.1152/ajpcell.00404.2009.
4. Wainwright C.E., Elborn J.S., Ramsey B.W., Marigowda G., Huang X., Cipolli M., et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N. Engl. J. Med. 2015, 373:220-231. 10.1056/NEJMoa1409547.
5. Veit G., Avramescu R.G., Perdomo D., Phuan P.-W., Bagdany M., Apaja P.M., et al. Some gating potentiators, including VX-770, diminish δF508-CFTR functional expression. Sci. Transl. Med. 2014, 6:246ra97. 10.1126/scitranslmed.3008889.
6. Cholon D.M., Quinney N.L., Fulcher M.L., Esther C.R., Das J., Dokholyan N.V., et al. Potentiator ivacaftor abrogates pharmacological correction of δF508 CFTR in cystic fibrosis. Sci. Transl. Med. 2014, 6:246ra96. 10.1126/scitranslmed.3008680.
7. Pedemonte N., Zegarra-Moran O., Galietta L.J.V. High-throughput screening of libraries of compounds to identify CFTR modulators. Methods Mol. Biol. (Clifton, NJ) 2011, 741:13-21. 10.1007/978-1-61779-117-8_2.
8. Van Goor F., Straley K.S., Cao D., González J., Hadida S., Hazlewood A., et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 290:L1117-L1130. 10.1152/ajplung.00169.2005.
9. Wang Y., Loo T.W., Bartlett M.C., Clarke D.M. Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants. Biochem. J. 2007, 406:257-263. 10.1042/BJ20070478.
10. Wang Y., Loo T.W., Bartlett M.C., Clarke D.M. Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones. Mol. Pharmacol. 2007, 71:751-758. 10.1124/mol.106.029926.
11. Zhou Z., Gong Q., January C.T. Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects. J. Biol. Chem. 1999, 274:31123-31126.
12. Ficker E., Obejero-Paz C.A., Zhao S., Brown A.M. The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations. J. Biol. Chem. 2002, 277:4989-4998. 10.1074/jbc.M107345200.
13. Aridor M., Hannan L.A. Traffic jam: a compendium of human diseases that affect intracellular transport processes. Traffic 2000, 1:836-851.
14. Szent-Gyorgyi C., Schmidt B.F., Schmidt B.A., Creeger Y., Fisher G.W., Zakel K.L., et al. Fluorogen-activating single-chain antibodies for imaging cell surface proteins. Nat. Biotechnol. 2008, 26:235-240. 10.1038/nbt1368.
15. Holleran J.P., Glover M.L., Peters K.W., Bertrand C.A., Watkins S.C., Jarvik J.W., et al. Pharmacological rescue of the mutant cystic fibrosis transmembrane conductance regulator (CFTR) detected by use of a novel fluorescence platform. Mol. Med. (Cambridge, MA) 2012, 18:685-696. 10.2119/molmed.2012.00001.
16. Zhang J.-H., Chung T.D.Y., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 1999, 4:67-73. 10.1177/108705719900400206.